Screening for alternative splicing of lncRNA Dleu2 in the mouse liver cell line AML-12

Kay,Matthew Krivacka; Zhang,Jian; Choudhury,Mahua

doi:10.3892/br.2021.1426

Screening for alternative splicing of lncRNA Dleu2 in the mouse liver cell line AML-12

Authors:
- Matthew Krivacka Kay
- Jian Zhang
- Mahua Choudhury
View Affiliations

Affiliations: Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, Texas, TX 77843, USA
Published online on: April 1, 2021 https://doi.org/10.3892/br.2021.1426
Article Number: 50

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The long non coding RNA deleted in leukemia 2 gene (Dleu2) has recently been demonstrated to be an active player in the progression of several types of cancer, including hepatocellular carcinoma. Dleu2 may serve a role in modulating the downstream effects‑mediated by alternative splicing of its multiple exons. However, the proportional expression of these alternative splicing populations of the Dleu2 exons is currently unknown. To determine how Dleu2 could be affected by alternative splicing, a series of alternative splicing primer sets were designed to investigate which transcripts were preferentially activated when Dleu2 was targeted for downregulation or upregulation. A specific Dleu2 small interfering RNA that targeted an exon upstream of the tumor suppressor microRNA site significantly knocked down Dleu2 expression across all the primer sets used, which targeted 13 different alternative splicing transcripts over 5 different promoter sites in the mouse liver cell line, AML‑12. Similarly, 50 µM Resveratrol led to significant upregulation of Dleu2 in 11 alternative splicing transcripts. These results show that Dleu2 is capable of successful modulation across alternative splicing transcripts that can be screened, and also that Resveratrol can be a potential nutraceutical, which may potentially lead to novel approaches in the use of lncRNA Dleu2 for diagnostics and regulation.

View Figures

View References

1	Klein UL, Lia M, Shen Q, Smith PM, Tang H, Mo T, Crespo M, Siegel R, Bhagat G and Dalla-Favera R: The DLEU2/Mir-15a/Mir-16-1 locus, commonly deleted in B-cell chronic Lymphocytic leukemia (CLL), controls B-cell compartment expansion and its deletion leads to CLL in mice. Blood. 112(25)2008.
2	Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G, et al: The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 17:28–40. 2010.PubMed/NCBI View Article : Google Scholar
3	Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M and Lichter P: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 343:1910–1916. 2000.PubMed/NCBI View Article : Google Scholar
4	Kalachikov S, Migliazza A, Cayanis E, Fracchiolla NS, Bonaldo MF, Lawton L, Jelenc P, Ye X, Qu X, Chien M, et al: Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics. 42:369–377. 1997.PubMed/NCBI View Article : Google Scholar
5	Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, et al: Characterization of the 13q14 tumor suppressor locus in CLL: Identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 61:6640–6648. 2001.PubMed/NCBI
6	Corcoran MM, Rasool O, Liu Y, Iyengar A, Grander D, Ibbotson RE, Merup M, Wu X, Brodyansky V, Gardiner AC, et al: Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood. 91:1382–1390. 1998.PubMed/NCBI
7	Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, Grandér D, Iyengar A, Baranova A, Kashuba V, Merup M, et al: Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene. 15:2463–2473. 1997.PubMed/NCBI View Article : Google Scholar
8	Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z and He J: Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 393:40–51. 2017.PubMed/NCBI View Article : Google Scholar
9	Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grandér D and Corcoran MM: DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res. 315:2941–2952. 2009.PubMed/NCBI View Article : Google Scholar
10	Jiang XP, Ai WB, Wan LY, Zhang YQ and Wu JF: The roles of microRNA families in hepatic fibrosis. Cell Biosci. 7(34)2017.PubMed/NCBI View Article : Google Scholar
11	Chen Z, Zhang J, Zhang Z, Feng Z, Wei J, Lu J, Fang Y, Liang Y, Cen J, Pan Y, et al: The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell Death Dis. 8(e2859)2017.PubMed/NCBI View Article : Google Scholar
12	Xu B, Gong X, Zi L, Li G, Dong S, Chen X and Li Y: Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA-455. Cancer Sci. 110:1676–1685. 2019.PubMed/NCBI View Article : Google Scholar
13	Boue S, Letunic I and Bork P: Alternative splicing and evolution. BioEssays. 25:1031–1034. 2003.PubMed/NCBI View Article : Google Scholar
14	Modrek B and Lee C: A genomic view of alternative splicing. Nat Genet. 30:13–19. 2002.PubMed/NCBI View Article : Google Scholar
15	Pan Q, Shai O, Lee LJ, Frey BJ and Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 40:1413–1415. 2008.PubMed/NCBI View Article : Google Scholar
16	Soergel DAW, Lareau LF and Brenner SE: Regulation of gene expression by coupling of alternative splicing and NMD. In: Madame Curie Bioscience Database. Landes Bioscience, Austin, TX, 2000-2013.
17	Edwalds-Gilbert G: Regulation of mRNA Splicing by Signal Transduction. Nat Educ. 3(43)2010.
18	Tress ML, Abascal F and Valencia A: Alternative splicing may not be the key to proteome complexity. Trends Biochem Sci. 42:98–110. 2017.PubMed/NCBI View Article : Google Scholar
19	Ankö ML and Neugebauer KM: Long noncoding RNAs add another layer to pre-mRNA splicing regulation. Mol Cell. 39:833–834. 2010.PubMed/NCBI View Article : Google Scholar
20	Romero-Barrios N, Legascue MF, Benhamed M, Ariel F and Crespi M: Splicing regulation by long noncoding RNAs. Nucleic Acids Res. 46:2169–2184. 2018.PubMed/NCBI View Article : Google Scholar
21	Gil N and Ulitsky I: Production of spliced long noncoding RNAs specifies regions with increased enhancer activity. Cell Syst. 7:537–547.e3. 2018.PubMed/NCBI View Article : Google Scholar
22	Soreq L, Guffanti A, Salomonis N, Simchovitz A, Israe Z, Bergman H and Soreq H: Long non-coding RNA and alternative splicing modulations in Parkinson's leukocytes identified by RNA sequencing. PLOS Comput Biol. 10(e1003517)2014.PubMed/NCBI View Article : Google Scholar
23	Kiegle EA, Garden A, Lacchini E and Kater MM: A genomic view of alternative splicing of long non-coding RNAs during rice seed development reveals extensive splicing and lncRNA gene families. Front Plant Sci. 9(115)2018.PubMed/NCBI View Article : Google Scholar
24	Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG, Bennett R, et al: Ensembl 2020. Nucleic Acids Res. 48:D682–D688. 2020.PubMed/NCBI View Article : Google Scholar
25	Williams M, Cheng YY, Kirschner MB, Sarun KH, Schelch K, Winata P, McCaughan B, Kao S, Van Zandwijk N and Reid G: Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Oncotarget. 10:4125–4138. 2019.PubMed/NCBI View Article : Google Scholar
26	Ma W, Zhang CQ, Dang CX, Cai HY, Li HL, Miao GY, Wang JK and Zhang LJ: Upregulated long-non-coding RNA DLEU2 exon 9 expression was an independent indicator of unfavorable overall survival in patients with esophageal adenocarcinoma. Biomed Pharmacother. 113(108655)2019.PubMed/NCBI View Article : Google Scholar
27	Morenos L, Chatterton Z, Ng JL, Halemba MS, Parkinso-Bates M, Mechinaud F, Elwood N, Saffery R and Wong NC: Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Mol Cancer. 13(123)2014.PubMed/NCBI View Article : Google Scholar
28	Park MH, Gutiérrez-García AK and Choudhury M: Mono-(2-ethylhexyl) phthalate aggravates inflammatory response via sirtuin regulation and inflammasome activation in RAW 264.7 cells. Chem Res Toxicol. 32:935–942. 2019.PubMed/NCBI View Article : Google Scholar
29	Guo Y, Bai M, Lin L, Huang J, An Y, Liang L, Liu Y and Huang W: LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2. Biomed Pharmacother. 118(109272)2019.PubMed/NCBI View Article : Google Scholar
30	Wu W, Zhao Y, Gao E, Li Y, Guo X, Zhao T, He W and Zhang H: LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p. J Cell Mol Med. 24:441–450. 2020.PubMed/NCBI View Article : Google Scholar
31	Zhou Y, Shi H, Du Y, Zhao G, Wang X, Li Q, Liu J, Ye L, Shen Z, Guo Y, et al: lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis. Aging (Albany NY). 11:7386–7401. 2019.PubMed/NCBI View Article : Google Scholar
32	Lu T, Wang R, Cai H and Cui Y: Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis. Biomed Pharmacother. 123(109650)2020.PubMed/NCBI View Article : Google Scholar
33	Zheng ZM and Wang X: Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta. 1809:668–677. 2011.PubMed/NCBI View Article : Google Scholar
34	Corcoran MM, Hammarsund M, Zhu C, Lerner M, Kapanadze B, Wilson B, Larsson C, Forsberg L, Ibbotson RE, Einhorn S, et al: DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse. Genes Chromosomes Cancer. 40:285–297. 2004.PubMed/NCBI View Article : Google Scholar